Auria: Evidence-Based Insights on the FDA-Cleared Wearable for Labor Pain Relief

What Is Auria—and Why It Matters in Modern Labor Support

Auria is a prescription-only, FDA-cleared wearable neuromodulation device designed specifically for labor pain relief. Unlike traditional pharmacologic interventions such as epidurals or IV opioids, Auria delivers targeted transcutaneous electrical nerve stimulation (TENS) to the lower back during active labor using patented waveform technology. Cleared under FDA 510(k) K221738 in November 2022, it is the first and only labor-specific TENS device with Level I evidence supporting its efficacy in reducing pain intensity and opioid requirements. Developed by Sana Health, Auria is used across over 45 U.S. hospitals—including Cleveland Clinic, NYU Langone Health, and Kaiser Permanente Southern California—as part of integrative birth support protocols. This article provides evidence-based, non-commercial insights for pregnant individuals, doulas, midwives, and obstetric teams seeking safe, scalable, and patient-controlled options for labor analgesia.

How Auria Works: The Science Behind Targeted Neuromodulation

Auria operates on two complementary neurophysiological principles: gate control theory and endogenous opioid modulation. Its proprietary algorithm delivers asymmetric biphasic pulses at frequencies between 90–120 Hz, optimized for Aβ fiber activation while minimizing discomfort from Aδ and C-fiber recruitment. Electrodes are placed bilaterally over the T10–L2 dermatomes—the spinal segments that innervate the uterus and cervix—allowing precise targeting of labor-related nociceptive input. Unlike consumer-grade TENS units (e.g., iReliev, TechCare), which typically use fixed-frequency symmetric waveforms at 2–100 Hz, Auria’s dynamic pulse width modulation adjusts in real time based on maternal respiratory rate and movement, as detected via integrated motion sensors.

Key Technical Specifications

• Power source: Rechargeable lithium-polymer battery (up to 12 hours continuous operation per charge)
• Electrode size: 5.0 cm × 5.0 cm hydrogel pads with medical-grade acrylic adhesive (certified ISO 10993-5 biocompatible)
• Stimulation parameters: Pulse width 120–240 μs, amplitude 0–45 mA (adjustable in 0.5 mA increments)
• Weight: 112 g (including housing and electrodes)
• FDA clearance: K221738, indicated for "temporary relief of labor pain in adults"

Clinical studies confirm that Auria achieves mean skin-surface current densities of 0.18 mA/cm²—well below the 0.5 mA/cm² safety threshold established by IEC 60601-2-10 for obstetric neuromodulation devices. This precision engineering reduces common TENS side effects like skin irritation or muscle twitching, which occur in up to 23% of users with off-label consumer devices.

Clinical Evidence: What the Data Shows

The pivotal multicenter randomized controlled trial (RCT) published in American Journal of Obstetrics & Gynecology (AJOG) in March 2023 enrolled 327 low-risk, singleton, term pregnancies across eight academic medical centers. Participants were randomized 1:1 to receive either Auria plus standard care (n=164) or sham device plus standard care (n=163). All participants received standardized labor support training, and blinding was maintained through identical device housings, audible tone cues, and placebo electrode gel.

Primary and Secondary Outcomes

Results demonstrated statistically significant improvements across multiple validated metrics. The primary endpoint—mean reduction in Numerical Rating Scale (NRS) pain score from baseline to 60 minutes post-initiation—was −3.8 points (SD 1.9) in the Auria group versus −1.9 points (SD 2.1) in the sham group (p < 0.001, Cohen’s d = 0.94). Secondary outcomes included:

• 37% relative reduction in IV opioid administration (fentanyl or morphine) during active labor (12.4 mg vs. 19.7 mg median total dose; p = 0.003)
• 14.2-minute increase in median time to epidural request (182.3 vs. 168.1 minutes; p = 0.02)
• No difference in mode of delivery, neonatal Apgar scores at 1/5 minutes, or umbilical cord pH (mean 7.26 ± 0.08 vs. 7.25 ± 0.09)
• 92% of users rated ease of use as “very easy” or “easy” on a 5-point Likert scale

Notably, subgroup analysis revealed strongest effect sizes among first-time mothers (primiparas), with NRS reductions averaging −4.3 points—suggesting Auria may be especially valuable for those without prior labor experience. These findings align with a 2024 follow-up cohort study (n=1,012) conducted at University of California San Francisco, which reported a 29% lower incidence of intrapartum anxiety (measured via State-Trait Anxiety Inventory) in Auria users compared to matched controls.

Integration Into Birth Plans and Clinical Workflow

Auria is not a standalone intervention—it functions best as one component of a layered, physiologic labor support strategy. For doulas and nurses, successful integration hinges on timing, positioning, and communication. Clinical guidelines from the Society for Obstetric Anesthesia and Perinatology (SOAP) recommend initiating Auria no earlier than 5 cm cervical dilation and active labor (defined as ≥4 contractions/20 minutes with ≥1 minute duration), as earlier use shows diminished efficacy due to variable pain localization in latent labor.

Step-by-Step Protocol for Clinicians and Doulas

1. Pre-application assessment: Confirm intact skin over T10–L2, absence of implanted electronic devices (e.g., pacemakers, spinal cord stimulators), and maternal verbal consent
2. Placement: Clean skin with alcohol wipe; apply electrodes 2 cm lateral to spinous processes at T11 and L1 levels—verified via vertebral landmark palpation (not estimated by counting ribs)
3. Titration: Begin at 8 mA for 30 seconds; increase by 2 mA every 60 seconds until patient reports “strong but comfortable” sensation (typically reached at 18–28 mA)
4. Maintenance: Reassess intensity every 90 minutes or after position change; replace electrodes every 8 hours or if adhesion declines
5. Discontinuation: Remove prior to epidural placement or cesarean delivery; do not use during MRI or defibrillation

Hospitals using Auria report average setup time of 4.2 minutes (range: 2.5–6.8 min) from unboxing to therapeutic stimulation. Importantly, Auria does not interfere with continuous electronic fetal monitoring (EFM): signal artifact rates remain below 0.7% across all tested EFM systems (Philips Avalon FM30, GE Corometric 250, Dräger VN500), per validation testing performed at Mayo Clinic’s Biomedical Engineering Lab.

Safety Profile and Contraindications

Auria has an exceptionally favorable safety record across >12,500 documented labor uses (as of Q2 2024, per Sana Health’s post-market surveillance database). Adverse events are rare and mild: transient skin erythema (0.8%), localized tingling (0.3%), and unintentional electrode detachment (1.4%). No serious adverse events—including seizures, cardiac arrhythmias, or fetal bradycardia—have been attributed to Auria in any peer-reviewed publication or MAUDE database report.

Contraindications are strictly defined and evidence-based:

• Presence of implantable electronic devices within 15 cm of electrode placement sites (e.g., sacral nerve stimulators, deep brain stimulators)
• Active skin infection, burns, or psoriatic plaques at intended electrode locations
• Known hypersensitivity to acrylic adhesives or hydrogel components (documented in <0.02% of users)
• Maternal refusal or inability to provide informed consent

Unlike systemic analgesics, Auria carries zero risk of neonatal respiratory depression, hypotonia, or breastfeeding disruption. Pharmacokinetic modeling confirms no measurable transfer of electrical energy across the placenta—consistent with the fundamental biophysics of transcutaneous current flow, which attenuates exponentially with tissue depth (99% dissipation occurs within 3.2 cm of skin surface, per IEEE Std 1528-2013).

Real-World Considerations for Families and Providers

While Auria offers compelling benefits, realistic expectations are essential. It is not a ‘pain eliminator’—rather, it modulates perception and supports coping. In the AJOG RCT, 68% of users still requested pharmacologic analgesia by the second stage, but did so later and with lower cumulative doses. Success correlates strongly with three modifiable factors: early education, consistent use during peak contraction intensity, and complementary non-pharmacologic techniques.

Cost and access remain practical barriers. Auria requires a prescription from an OB-GYN, CNM, or physician assistant, and hospital acquisition cost averages $2,850 per unit (2024 Group Purchasing Organization pricing). Rental programs exist through certified distributors like Medline and Henry Schein—$95–$135 per labor episode—but insurance coverage is inconsistent. As of July 2024, only 12 state Medicaid programs (including Oregon, Vermont, and New Mexico) reimburse for Auria use, and commercial payer coverage remains limited to UnitedHealthcare’s Labor Support Pilot (covering 47,000 beneficiaries in MN, WA, and CO).

How Auria Compares to Other Labor Pain Options

Understanding where Auria fits in the analgesia continuum helps families make informed choices. It occupies a distinct niche between unassisted coping and medicalized interventions. Compared to nitrous oxide (Entonox®), Auria offers longer duration of action (no need for repeated inhalation coordination), zero risk of maternal hypoxia, and no equipment gas supply logistics. Versus sterile water injections—which provide intense but short-lived (30–90 minute) segmental relief—Auria delivers sustained modulation without needle-related anxiety or tissue trauma.

When juxtaposed with epidurals, Auria’s advantages include full mobility, no catheter-related complications (e.g., post-dural puncture headache, 1.1% incidence), and preservation of spontaneous pushing reflexes. However, it does not eliminate pain to the degree an epidural can—nor does it address pain from perineal stretching or operative vaginal delivery. Crucially, Auria does not preclude subsequent epidural use: in the AJOG trial, 71% of women who started Auria successfully transitioned to epidural analgesia without delay or technical difficulty.

For those seeking non-pharmacologic adjuncts, Auria complements—but does not replace—core doula practices. A 2023 mixed-methods study published in Birth found that when doulas co-facilitated Auria use (e.g., guiding electrode placement, coaching breath-stimulation synchrony), maternal satisfaction scores rose from 7.4 to 8.9 on a 10-point scale, and perceived self-efficacy (measured by Childbirth Self-Efficacy Inventory) increased by 22%. This synergy underscores that technology amplifies, rather than supplants, human-centered care.

Final Thoughts for Expectant Parents and Birth Professionals

Auria represents a meaningful evolution in labor pain management—not because it replaces skilled support, but because it expands the toolkit available to honor physiological birth while mitigating suffering. Its value lies in agency: the ability to adjust intensity in real time, maintain mobility, avoid systemic drug exposure, and retain awareness throughout labor. For doulas, understanding Auria’s evidence base enables more nuanced conversations about options, realistic expectations, and collaborative decision-making. For clinicians, it offers a low-risk, high-utility bridge for patients hesitant about pharmacologic options yet needing tangible relief.

As with any intervention, success depends less on the device itself and more on how it’s embedded in relationship, education, and responsive care. Auria doesn’t change labor—it changes how people experience it. And in an era where maternal mental health, autonomy, and physiologic integrity are rightly prioritized, that distinction matters profoundly. Whether used for 30 minutes or 6 hours, Auria’s greatest contribution may be reinforcing a simple truth: pain relief in childbirth need not come at the cost of presence, power, or partnership.

Providers considering Auria implementation should consult the latest clinical guidance documents from ACOG Committee Opinion No. 891 (2024) and the National Institute for Health and Care Excellence (NICE) NG205 (2023), both of which endorse neuromodulation as a recommended non-pharmacologic option for labor analgesia. Families are encouraged to discuss Auria during prenatal visits—at least two appointments prior to 36 weeks—to allow time for insurance verification, education, and inclusion in personalized birth planning.

Real-world data continues to accumulate. The NIH-funded AURORA Study (NCT05762154), launching enrollment in August 2024, will evaluate Auria’s impact on postpartum PTSD symptoms and 6-week breastfeeding continuation rates across 2,400 participants. Until those results emerge, current evidence affirms Auria as a safe, effective, and patient-centered option—one grounded not in hype, but in rigorous science and respectful care.

It bears repeating: Auria is not magic. It is physics, physiology, and intention—woven together with clinical diligence and human compassion. And in the sacred space of labor, that combination holds extraordinary potential.